Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)

Abstract

The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) is an internationally recognized, evidence-based psychometric screening instrument developed under the auspices of the World Health Organization (WHO) to address the widespread public health burden associated with psychoactive substance use. Conceived by an international consortium of addiction researchers, the ASSIST fills a critical clinical gap by providing a unified, multi-substance screening protocol tailored primarily for primary healthcare, general medical, and community-based settings. The instrument systematically evaluates lifetime and past-three-month non-medical use across ten distinct drug classes: tobacco products, alcoholic beverages, cannabis, cocaine, amphetamine-type stimulants, inhalants, sedatives or sleeping pills, hallucinogens, opioids, and other unspecified substances. Comprising eight operational items, the ASSIST assesses frequency of use, craving and compulsion, health, social, legal, and financial complications, failure to fulfill major role obligations, interpersonal concern from family or friends, unsuccessful attempts to cut down or control consumption, and high-risk behaviors involving intravenous injection.

For each substance class, the instrument yields a continuous Specific Substance Involvement Score (SSIS) ranging from 0 to 39 (0 to 31 for tobacco), which categorizes respondents into three evidence-based risk tiers: low risk, moderate risk, and high risk. Psychometric validation studies conducted across diverse multinational samples demonstrate that the ASSIST exhibits robust psychometric properties, including high internal consistency (Cronbach’s alpha coefficients typically ranging from 0.77 to 0.94 across substance categories), strong test-retest reliability ($r = 0.58$ to $0.90$), and excellent concurrent validity when benchmarked against legacy single-substance screens such as the Alcohol Use Disorders Identification Test (AUDIT), the Drug Abuse Screening Test (DAST), and structured clinical diagnostic interviews for DSM-IV and ICD-10 substance abuse and dependence. By linking directly to an evidence-based Brief Intervention (ASSIST-BI) framework rooted in motivational interviewing, the ASSIST serves not merely as a diagnostic case-finding tool, but as the psychometric foundation for secondary prevention and targeted clinical escalation across global healthcare systems.

Keywords

ASSIST, World Health Organization, substance use screening, addiction psychometrics, alcohol screening, tobacco dependence, illicit drug use, hazardous substance use, brief intervention, Specific Substance Involvement Score, primary healthcare screening, psychometric validation, risk stratification, substance-related disorders

Authors

The Alcohol, Smoking and Substance Involvement Screening Test was developed by the WHO ASSIST Working Group, a collaborative international initiative coordinated by the Department of Mental Health and Substance Dependence at the World Health Organization (Geneva, Switzerland). Key investigators and psychometricians who spearheaded the conception, multi-site field trials, and validation include:

• Robert Ali, Drug and Alcohol Services South Australia (DASSA) and the WHO Collaborating Centre in the Treatment of Drug and Alcohol Problems, University of Adelaide, Adelaide, Australia.
• Rachel Humeniuk, Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide, Australia.
• Thomas F. Babor, Department of Community Medicine and Health Care, University of Connecticut School of Medicine, Farmington, Connecticut, USA.
• Michael Farrell, National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom (subsequently Director of the National Drug and Alcohol Research Centre, UNSW, Australia).
• Maria Lucia O. Souza-Formigoni, Department of Psychobiology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
• Jiraporn Jittiwutikarn, Northern Substance Abuse Treatment Centre, Department of Medical Services, Ministry of Public Health, Chiang Mai, Thailand.
• Vladimir Poznyak and Maristela G. Monteiro, Department of Mental Health and Substance Abuse, World Health Organization, Geneva, Switzerland.
• Steve Simon and David A. Newcombe, contributing psychometricians and clinical epidemiologists within the international field trial consortium.

Purpose

The primary clinical and public health objective of the ASSIST is the early detection, quantification, and risk stratification of psychoactive substance use among individuals presenting to generalist, non-specialized healthcare settings. Historically, addiction screening in primary care suffered from significant fragmentation: clinicians were obliged to administer separate, disparate instruments for different substances—such as the AUDIT or CAGE for alcohol, the Fagerström Test for Nicotine Dependence (FTND) for tobacco, and the DAST or CAGE-AID for illicit drugs. This approach proved unwieldy, time-prohibitive, and conceptually disjointed, particularly given the high prevalence of polysubstance use in clinical populations. The ASSIST was specifically engineered to resolve this clinical impasse by offering an all-in-one, comprehensive screening mechanism that concurrently assesses all major psychoactive substance classes using standardized, comparable scoring metrics.

From an epidemiological and clinical triage perspective, the ASSIST operates on the principle that psychoactive substance consumption exists along a broad spectrum—ranging from total abstinence and low-risk experimental use to hazardous use, harmful use, and severe neurobiological dependence. Traditional medical systems frequently fail to intervene until patients manifest acute physical pathology, severe psychiatric comorbidities, or catastrophic psychosocial disintegration. The ASSIST is designed to disrupt this reactive trajectory by identifying hazardous and harmful use at early, preclinical, or sub-syndromal stages. Hazardous use denotes a pattern of substance consumption that elevates the risk of future adverse physical or psychological outcomes, whereas harmful use indicates that physical, psychological, or social damage has already materialized, though formal physiological dependence criteria may not yet be met.

Furthermore, the ASSIST serves as the assessment gateway to the Screening, Brief Intervention, and Referral to Treatment (SBIRT) paradigm. Rather than merely categorizing a patient dichotomously as “addicted” or “non-addicted,” the ASSIST generates a continuous Specific Substance Involvement Score (SSIS) for each drug class. This granular measurement maps directly into tiered clinical pathways: low-risk individuals receive general health promotion and positive reinforcement; moderate-risk individuals are provided structured brief interventions grounded in motivational interviewing; and high-risk individuals are triaged into specialized addiction treatment services for comprehensive medical detoxification, pharmacotherapy, and intensive psychotherapy.

In academic and clinical research contexts, the ASSIST provides an invaluable standardized endpoint for epidemiological surveillance, clinical trials evaluating pharmacotherapies or behavioral interventions, and health systems research monitoring trends in polysubstance use across diverse socio-demographic cohorts. Its cross-cultural validity ensures that research findings generated across different global regions can be compared with rigorous psychometric equivalence.

Psychological Construct

The latent psychological construct quantified by the ASSIST is Substance Involvement, operationalized as a multidimensional, progressive severity continuum reflecting an individual’s behavioral, cognitive, physiological, and psychosocial engagement with a specific psychoactive substance class. Rather than conceptualizing substance use disorders as binary categorical states, the psychometric architecture of the ASSIST views substance involvement as an escalating trait along which consumption patterns translate into varying degrees of psychological salience, impaired volition, and collateral harm.

The construct encompasses several distinct yet highly intercorrelated domains, captured across the eight operational items of the instrument:

• Temporal Exposure and Recency (Items 1 and 2): Quantifies lifetime exposure (lifetime experiment vs. lifetime abstinence) and current consumption density over the preceding three months. The three-month window was selected deliberately to capture contemporary, clinically actionable behavior while attenuating the historical recall bias inherent in lifetime-only assessments. Frequency of past-three-month use provides the foundational behavioral baseline of exposure intensity.
• Compulsion and Psychological Craving (Item 3): Measures the subjective cognitive and emotional salience of the substance, specifically the frequency of experiencing an overwhelming urge, strong desire, or craving to use. Craving represents a hallmark neurobehavioral facet of dependence, reflecting dopaminergic and glutamatergic dysregulation within the mesocorticolimbic reward circuitry. In the ASSIST construct, craving captures the transition from voluntary, goal-directed consumption to habitual, incentive-sensitized use.
• Multidimensional Substance-Related Problems (Item 4): Assesses the manifestation of negative externalities secondary to substance use across four explicit domains: physical health complications (e.g., organ toxicity, cognitive impairment, respiratory dysfunction), interpersonal/social disruptions (e.g., relationship dissolution, domestic discord), legal conflicts (e.g., arrests, civil disputes), and economic strain (e.g., unmanageable expenditure, debt). This dimension measures the transition from asymptomatic hazardous use to overt harmful use.
• Role Impairment and Behavioral Dysregulation (Item 5): Evaluates functional disability, specifically the failure to fulfill major developmental, social, or occupational responsibilities (e.g., academic absenteeism, workplace termination, parental neglect). Notably, this item is intentionally omitted for tobacco, as nicotine dependence rarely causes acute functional incapacity or catastrophic failure of social role obligations, illustrating the psychometric sensitivity of the tool to substance-specific phenomenology.
• Interpersonal Concern and Social Recognition (Item 6): Captures external behavioral markers of problematic use as observed by family members, romantic partners, friends, employers, or healthcare providers. Because substance users frequently engage in psychological defense mechanisms—such as denial, minimization, or rationalization—third-party concern serves as a robust psychometric proxy for objective, externally observable behavioral disruption.
• Impaired Volitional Control (Item 7): Measures executive control failure, operationalized as unsuccessful attempts to reduce, control, or cease substance consumption despite an explicit conscious intention to do so. Inability to regulate consumption constitutes a primary diagnostic criterion for substance dependence in both the DSM and ICD systems, reflecting compromised prefrontal inhibitory control over subcortical reward mechanisms.
• High-Risk Route of Administration (Item 8): Although not factored into the individual Specific Substance Involvement Scores, lifetime and recent non-medical injection drug use constitutes an independent, high-potency risk marker for blood-borne viral transmission (e.g., HIV, Hepatitis C, Hepatitis B), bacterial endocarditis, and lethal overdose.

Theoretical Framework

The ASSIST is theoretically anchored in the intersection of public health epidemiology, cognitive-behavioral addiction theory, and the Transtheoretical Model of Health Behavior Change. Unlike classical disease models of addiction—which historically posited a strict bimodal typology distinguishing “normal drinkers/users” from “addicts/alcoholics”—the ASSIST is grounded in the Continuum of Risk Model pioneered by Thomas F. Babor and colleagues under the auspices of the World Health Organization.

The Continuum of Risk framework asserts that substance-related pathology occurs across a continuous gradient of biological exposure and behavioral engagement. At the population level, the aggregate burden of substance-related disease, accidents, and social morbidity is driven far more heavily by the large proportion of individuals engaged in “hazardous” and “harmful” consumption than by the relatively smaller proportion of individuals exhibiting end-stage, chronic physiological dependence. Consequently, psychometric instruments must be calibrated to detect subtle shifts across the early and intermediate zones of this spectrum, rather than serving solely as blunt diagnostic instruments for severe dependency.

At the psychological and behavioral level, the ASSIST aligns with Incentive Sensitization Theory (Robinson & Berridge) and Neurocognitive Dual-Process Models of addiction. These frameworks posit that chronic psychoactive substance exposure induces neuroadaptations in the mesolimbic dopamine system that hypersensitize the brain to substance-related cues (“wanting” or craving, indexed by Item 3), while progressively eroding top-down prefrontal executive regulation over automated drug-seeking schemata (loss of control, indexed by Item 7). As automaticity strengthens, the user persists in drug administration despite accumulating adverse physical, financial, and relational consequences (Item 4) and severe occupational role failure (Item 5).

Finally, the ASSIST was explicitly engineered to interface synergistically with the Transtheoretical Model (TTM) of Prochaska and DiClemente and the principles of Motivational Interviewing formulated by Miller and Rollnick. The TTM posits that individuals move through distinct stages of change: Precontemplation, Contemplation, Preparation, Action, and Maintenance. Screening tools that merely deliver a pejorative diagnostic label often provoke defensive resistance, entrenching individuals in Precontemplation. In contrast, the ASSIST operationalizes substance involvement as a transparent, objective risk score that can be integrated into the FRAMES model of brief intervention:

• Feedback: Providing personalized, non-judgmental psychometric feedback on specific risk scores relative to normative benchmarks.
• Responsibility: Emphasizing that behavior change is entirely within the patient’s personal agency.
• Advice: Offering clear, professional guidance regarding the reduction or cessation of substance use.
• Menu: Outlining a menu of practical strategies for self-regulation and harm reduction.
• Empathy: Utilizing an empathetic, reflective, non-confrontational interpersonal style.
• Self-efficacy: Fostering optimism and confidence in the individual’s capacity to modify their substance-use habits.

Validity

The psychometric validity of the ASSIST has been established through rigorous, large-scale multicenter clinical investigations conducted across high-, middle-, and low-income nations, including Australia, Brazil, India, Thailand, the United Kingdom, and the United States (WHO ASSIST Working Group, 2002; Humeniuk et al., 2008). These investigations have systematically evaluated concurrent, construct, convergent, and discriminant validity against established legacy psychometric scales and structured psychiatric interviews.

Concurrent and Convergent Validity

Concurrent validity was established during Phase II and Phase III WHO field validation studies by correlating the Specific Substance Involvement Score (SSIS) of the ASSIST with established gold-standard reference scales. Across international test sites, the ASSIST alcohol score demonstrated robust Pearson correlation coefficients with the AUDIT ($r = 0.82$ to $0.89$), indicating strong psychometric convergence. For illicit drug classes, the ASSIST scores demonstrated strong, statistically significant correlations with the Drug Abuse Screening Test (DAST-20), with coefficients consistently ranging from $r = 0.76$ to $0.88$. Similarly, the ASSIST tobacco score correlated significantly with the Fagerström Test for Nicotine Dependence (FTND), yielding correlations between $r = 0.60$ and $0.75$. Furthermore, when benchmarked against the Addiction Severity Index (ASI) composite scores across medical, employment, legal, and family/social domains, the ASSIST subscales demonstrated moderate-to-high correlations ($r = 0.45$ to $0.72$), confirming that the tool accurately reflects broader life impairment secondary to drug use.

Construct and Discriminant Validity

Construct validity has been verified using known-groups comparisons and receiver operating characteristic (ROC) analyses. The ASSIST was administered alongside the Mini International Neuropsychiatric Interview (MINI-Plus) or the Composite International Diagnostic Interview (CIDI), which provide gold-standard clinical diagnoses of Substance Abuse and Substance Dependence under DSM-IV and ICD-10 criteria. Receiver operating characteristic analyses revealed exceptional diagnostic discriminative capacity. Across all substance categories, the Area Under the Curve (AUC) for distinguishing between non-dependent/low-risk individuals and those meeting clinical diagnostic criteria for abuse or dependence consistently ranged from $0.84$ to $0.96$:

• Alcohol: AUC for dependence $= 0.94$ (95% CI: $0.91-0.97$); an optimal cut-off score of 11 yielded a sensitivity of 89% and a specificity of 80% for hazardous/harmful use, while a cut-off score of 27 differentiated severe dependence with a sensitivity of 84% and specificity of 86%.
• Cannabis: AUC for dependence $= 0.91$ (95% CI: $0.87-0.95$); a cut-off of 4 distinguished low-risk from moderate-risk use (sensitivity 84%, specificity 83%), while a cut-off of 27 detected dependence (sensitivity 88%, specificity 91%).
• Cocaine and Amphetamines: AUC values for dependence $= 0.95$ and $0.92$, respectively, with high sensitivity ($>85%$) and specificity ($>88%$) at standard cut-off thresholds.
• Opioids: AUC for dependence $= 0.96$ (95% CI: $0.93-0.99$), demonstrating the highest diagnostic precision among the illicit substance classes.

These findings conclusively demonstrate that the ASSIST Specific Substance Involvement Scores accurately differentiate among healthy controls, non-dependent recreational/hazardous users, and chronically dependent clinical patients, providing empirical justification for its three-tier risk stratification system.

Reliability

The reliability of the ASSIST has been extensively substantiated across multiple languages, cultural settings, and clinical cohorts. Psychometric evaluations focus primarily on internal consistency (homogeneity of scale items) and test-retest reliability (temporal stability of scores under static clinical conditions).

Internal Consistency

During the Phase II international feasibility and reliability study ($N = 236$) and the Phase III multi-site validation study ($N = 1,047$), internal consistency was calculated separately for each substance category using Cronbach’s alpha ($lpha$). Because items 2 through 7 measure different operational manifestations of substance involvement within a single drug class, high internal consistency signifies that the items converge cohesively on the latent construct. The published reliability coefficients across multinational cohorts demonstrate high to excellent internal consistency:

• Tobacco: $\alpha = 0.80$ to $0.83$
• Alcohol: $\alpha = 0.82$ to $0.88$
• Cannabis: $\alpha = 0.84$ to $0.87$
• Cocaine: $\alpha = 0.86$ to $0.91$
• Amphetamine-type Stimulants: $\alpha = 0.87$ to $0.92$
• Inhalants: $\alpha = 0.81$ to $0.89$
• Sedatives/Hypnotics: $\alpha = 0.83$ to $0.88$
• Hallucinogens: $\alpha = 0.77$ to $0.85$
• Opioids: $\alpha = 0.89$ to $0.94$

Corrected item-total correlations across the substance subscales consistently exceed $0.50$, confirming that no single item introduces excessive error variance or detracts from scale homogeneity.

Test-Retest Reliability

Test-retest reliability was established by re-administering the ASSIST to clinical cohorts following an interval of two to fourteen days under conditions where no therapeutic intervention occurred between assessments. Intraclass correlation coefficients (ICCs) and Pearson product-moment correlation coefficients ($r$) for the Specific Substance Involvement Scores demonstrated substantial to excellent temporal stability:

• Alcohol SSIS: $r = 0.85$ (ICC $= 0.84$, $p < 0.001$)
• Cannabis SSIS: $r = 0.88$ (ICC $= 0.87$, $p < 0.001$)
• Tobacco SSIS: $r = 0.90$ (ICC $= 0.89$, $p < 0.001$)
• Cocaine SSIS: $r = 0.79$ (ICC $= 0.78$, $p < 0.001$)
• Amphetamines SSIS: $r = 0.77$ (ICC $= 0.76$, $p < 0.001$)
• Sedatives and Opioids SSIS: $r = 0.78$ to $0.86$

At the item level, Cohen’s kappa ($kappa$) statistics for categorical agreement across individual questions ranged from substantial ($kappa = 0.58$) to almost perfect ($kappa = 0.90$). The high stability coefficients confirm that the ASSIST scores are resistant to random measurement error, making the instrument highly suitable for longitudinal monitoring and pre-post intervention evaluations.

Factor Analysis

The structural dimensionality of the ASSIST has been rigorously explored using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA) across numerous empirical studies (e.g., Newcombe et al., 2005; Humeniuk et al., 2008; Hides et al., 2009). The primary structural question examined in psychometric literature is whether the items constituting each Specific Substance Involvement Score measure a single underlying latent dimension (unidimensionality) or separate distinct sub-constructs (e.g., consumption vs. adverse consequences vs. dependence symptoms).

Exploratory Factor Analysis (EFA)

Principal Axis Factoring and Principal Components Analysis with Varimax and Promax rotations performed on items 2 through 7 consistently yield a dominant single-factor solution for each substance domain. Across multiple international samples:

• Eigenvalues for the primary factor uniformly exceed $3.0$, accounting for between 54% and 72% of the total variance depending on the substance examined.
• Scree plots display sharp points of inflection following the initial factor, with secondary eigenvalues consistently dropping well below $1.0$ or hovering near baseline scree.
• Standardized factor loadings for items 2 through 7 onto the primary “Substance Involvement” factor are uniformly high: past-three-month frequency (Item 2) loadings range from $0.62$ to $0.78$; craving (Item 3) ranges from $0.68$ to $0.84$; substance-related problems (Item 4) ranges from $0.71$ to $0.86$; role failure (Item 5) ranges from $0.69$ to $0.85$; concern from others (Item 6) ranges from $0.58$ to $0.75$; and failed control (Item 7) ranges from $0.72$ to $0.88$.

Confirmatory Factor Analysis (CFA)

Confirmatory Factor Analyses evaluating a single-factor latent model for each substance category demonstrate excellent goodness-of-fit indices across diverse cultural adaptations. Standard structural equation modeling criteria indicate that the unidimensional model aligns robustly with empirical data:

• Comparative Fit Index (CFI): Values routinely exceed $0.95$, frequently achieving $0.97$ to $0.99$.
• Tucker-Lewis Index (TLI): Coefficients consistently fall between $0.94$ and $0.98$.
• Root Mean Square Error of Approximation (RMSEA): Estimates range from $0.038$ to $0.058$, remaining comfortably below the conventional $0.060$ threshold for close structural fit.
• Standardized Root Mean Square Residual (SRMR): Values consistently remain below $0.045$.

Higher-order and bifactor CFA models have also been investigated to assess whether a global “General Substance Vulnerability” factor (reflecting cross-substance polysubstance liability) underlies all ASSIST subscales simultaneously. Structural equation models reveal that while a broad general vulnerability factor exists, substance-specific involvement scores retain significant, indispensable unique variance. This finding provides rigorous psychometric justification for calculating and interpreting distinct risk scores for each drug class rather than collapsing all items into a single undifferentiated global substance score.

Instrument / Measurement Tool

The ASSIST is a structured screening instrument administered either as a clinician-facilitated semi-structured interview or as a self-administered digital or paper-and-pencil inventory. The clinical interview typically requires between 5 and 15 minutes, depending on the number of substance categories endorsed by the respondent.

• Test Type: Clinical Screening Instrument / Psychometric Risk Stratification Inventory.
• Target Population: Adults and adolescents presenting to primary healthcare, emergency departments, inpatient medical/surgical wards, mental health services, criminal justice settings, and specialized addiction clinics.
• Substance Classes Evaluated (10 categories):
  • a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.)
  • b. Alcoholic beverages (beer, wine, spirits, etc.)
  • c. Cannabis (marijuana, pot, grass, hash, etc.)
  • d. Cocaine (coke, crack, etc.)
  • e. Amphetamine-type stimulants (speed, diet pills, ecstasy, etc.)
  • f. Inhalants (nitrous oxide, glue, petrol, paint thinner, etc.)
  • g. Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, etc.)
  • h. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.)
  • i. Opioids (heroin, morphine, methadone, codeine, etc.)
  • j. Other substances (specified by respondent)
• Item Architecture: 8 core items incorporating conditional skip patterns:
  • Item 1: Screens lifetime non-medical use across all 10 substances. If negative for all substances, the interview terminates. If affirmative for any substance, Item 2 is administered for every endorsed substance.
  • Item 2: Evaluates consumption frequency during the past 3 months. If “Never” (0) across all endorsed substances, the interviewer skips Items 3, 4, and 5, advancing directly to Item 6.
  • Items 3, 4, and 5: Administered for each substance used within the past 3 months, assessing craving, health/social/legal/financial problems, and role failure (Note: Item 5 is omitted for tobacco).
  • Items 6 and 7: Administered for all substances endorsed in Item 1 (lifetime use), assessing third-party concern and impaired volitional control.
  • Item 8: Screens for non-medical injection drug use (lifetime and past 3 months).
• Response Scales and Scoring Weights: Responses are weighted according to psychometric calibrations established during WHO international trials:
  • Item 1: Dichotomous (No = 0, Yes = 3; clinical gating question).
  • Item 2 (Past-3-month frequency): Never = 0, Once or twice = 2, Monthly = 3, Weekly = 4, Daily or almost daily = 6.
  • Item 3 (Craving/Urge): Never = 0, Once or twice = 3, Monthly = 4, Weekly = 5, Daily or almost daily = 6.
  • Item 4 (Problems): Never = 0, Once or twice = 4, Monthly = 5, Weekly = 6, Daily or almost daily = 7.
  • Item 5 (Role failure): Never = 0, Once or twice = 5, Monthly = 6, Weekly = 7, Daily or almost daily = 8. (Omitted for tobacco).
  • Item 6 (Concern expressed): No, never = 0, Yes, but not in the past 3 months = 3, Yes, in the past 3 months = 6.
  • Item 7 (Failed control): No, never = 0, Yes, but not in the past 3 months = 3, Yes, in the past 3 months = 6.
  • Item 8 (Injecting risk): No, never = 0, Yes, but not in the past 3 months = 1, Yes, in the past 3 months = 2.
• Scoring Calculation and Risk Stratification:

  A Specific Substance Involvement Score (SSIS) is calculated separately for each substance by summing the numerical scores obtained on Items 2 through 7 (Questions $2 + 3 + 4 + 5 + 6 + 7$). For tobacco, the maximum possible score is 31; for all other substances, the maximum possible score is 39.

  • Alcohol Risk Categories:
    • Low Risk (Score 0–10): Individual is at low risk of health or social problems from current drinking patterns. Intervention: General health education and feedback.
    • Moderate Risk (Score 11–26): Individual is experiencing or at risk of experiencing health, social, or legal problems. Intervention: Brief Intervention (ASSIST-BI) including motivational interviewing and take-home self-help strategies.
    • High Risk (Score 27+): High likelihood of physiological dependence and severe substance-related complications. Intervention: Brief intervention and direct referral to addiction specialist services for comprehensive diagnostic evaluation, medical detoxification, or pharmacotherapy.
  • All Other Substances (Tobacco, Cannabis, Cocaine, Stimulants, Inhalants, Sedatives, Hallucinogens, Opioids, Other):
    • Low Risk (Score 0–3): Low risk of substance-related adverse consequences. Intervention: Positive reinforcement and general health advice.
    • Moderate Risk (Score 4–26): Hazardous or harmful consumption patterns. Intervention: Brief intervention (ASSIST-BI) tailored to the specific substance.
    • High Risk (Score 27+): Probable physiological dependence and severe functional impairment. Intervention: Immediate referral to specialized addiction treatment.

Permissions & Fee and Test Year

The Alcohol, Smoking and Substance Involvement Screening Test was formally introduced following extensive multinational development between 1997 and 2002. Version 3.0 (ASSIST V3.0), the definitive operational standard, was finalized and disseminated by the World Health Organization in 2002, with comprehensive clinical guidelines for primary care published in 2003 and full international validation results published in 2008.

The ASSIST is an open-access, public domain instrument produced by the World Health Organization. There are no fees, royalties, or licensing costs required to administer, reproduce, translate, or integrate the ASSIST into non-commercial clinical, academic, research, or public health programs. The World Health Organization retains copyright to preserve instrument integrity and ensure standard psychometric properties. Researchers and clinical institutions adapting or translating the instrument into regional languages or digital platforms are requested to adhere strictly to WHO translation guidelines and acknowledge the World Health Organization ASSIST Working Group in all resulting publications.

References

Henry-Edwards, S., Humeniuk, R., Ali, R., Poznyak, V., & Monteiro, M. (2003). The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Guidelines for use in primary care (Draft version 1.1 for field testing). World Health Organization. https://www.who.int/substance_abuse/activities/assist/en/

Hides, L., Cotton, S. M., Morrison, R., Quinn, C., & Lubman, D. I. (2009). The reliability and validity of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in first-episode psychosis. Addictive Behaviors, 34(10), 821–825. https://doi.org/10.1016/j.addbeh.2009.03.013

Humeniuk, R., Ali, R., Babor, T. F., Farrell, M., Formigoni, M. L., Jittiwutikarn, J., de Lacerda, R. B., Ling, W., Marsden, J., Monteiro, M., Poznyak, V., & Simon, S. (2008). Validation of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). Addiction, 103(6), 1039–1047. https://doi.org/10.1111/j.1360-0443.2007.02114.x

Humeniuk, R., Henry-Edwards, S., Ali, R., Poznyak, V., & Monteiro, M. G. (2010). The ASSIST-linked brief intervention for hazardous and harmful substance use: A manual for use in primary care. World Health Organization. https://apps.who.int/iris/handle/10665/44321

Newcombe, D. A., Humeniuk, R. E., & Ali, R. (2005). Validation of the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Report of results from the Australian site. Drug and Alcohol Review, 24(3), 217–226. https://doi.org/10.1080/09595230500170266

WHO ASSIST Working Group. (2002). The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Development, reliability and feasibility. Addiction, 97(9), 1183–1194. https://doi.org/10.1046/j.1360-0443.2002.00185.x

13. Items of the Scale (Questionnaire)